Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

RIT Oncology

2008 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

Marketer of pharmaceutical preparations. The company commercializes and develops ZEVALIN(R) ([90Y]-ibritumomab tiuxetan), which is a radioimmunotherapeutic drug, used for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma and patients who have rituximab-refractory follicular non-Hodgkin's lymphoma.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 501 Elliott Avenue West
  • Suite 400
  • Seattle, WA 98119
  • United States

RIT Oncology Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore RIT Oncology‘s full profile, request access.

Request full access to PitchBook

RIT Oncology Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore RIT Oncology‘s full profile, request access.

Request full access to PitchBook